Research Article
BibTex RIS Cite

Evaluation of PD1 and PDL1 Expressions in Squamous Cell Carcinoma and Lichen Planus

Year 2021, Volume: 12 Issue: 2, 147 - 157, 20.08.2021

Gamze Erkılınç , Onur Ertunç , Mehmet Kıran , Nermin Karahan , Havva Hilal Ayvaz , Dudu Dilek Yavuz , Zümrüt Arda Kaymak

https://doi.org/10.22312/sdusbed.816756

Abstract

Amaç: Programlı hücre ölümü 1 (PD1) T hücre ailesinde olan immün sistemi “down” regüle eden bir proteindir. PD ligandı 1 (PDL1) T hücre proliferasyonunu ve sitokin üretimini inhibe eden PD1 reseptör proteinidir. Dermiste lenfositik reaksiyon Liken Planusta (LP) lezyonun özelliği iken Skuamöz Hücreli Karsinomada (SHK) tümör hücrelerine karşı gelişen bir cevap olarak da izlenebilir. Çalışmamızda SHK ve LP’de PD1, PDL1’in epidermis ve lenfositik hücrelerdeki ekspresyonunu karşılaştırmayı amaçladık.
Materyal ve Method: Retrospektif randomize olarak dermiste LHİ (lenfositik hücre infiltrasyonu) yaygın olan 31 SCC ve 38 LP tanılı olgu çalışmamıza dahil edildi. PD1, PDL1’in; SHK, LP’ lerde dermisteki LHİ ekspresyonu ve epidermisteki hücrelerdeki ekspresyonları skorlandı.
Bulgular: PD1’in LHİ skoru LP’lerde anlamlı şekilde skor 1 ve 2 sık görülür iken (sırasıyla %44.7, %34.2), SHK’larda çoğunlukla skor 0 (%67.7) idi. PD1’in LP, SHK’da skor 3 hiç görülmez iken her iki grupta skor 0 çoğunlukta saptandı (LP: %76.3, SHK %87.1). PDL1’in LHİ skoru LP, SHK’da çoğunlukla skor 2, 3 olarak saptandı. PDL1’in deri skoru LP’lerde skor 2 ve 3 hiç görülmezken SHK’larda skor 2 %9.7, skor 3 %6.5 oranında görüldü.
Sonuç: PD1, PDL1 ile LP’lerin SHK’lara göre anlamlı şekilde lenfositik hücrelerde ekspresyonu, neoplastik durumlarda kullanımı sonrası yan etki olarak görülen LP ve benzeri deri reaksiyonlarını açıklayabileceğini düşünmekteyiz.

Keywords

PDL1 PD1 Squamous Cell Carcinoma Lichen Planus

References

  • 1) Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD1) positive tumor infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013;139(3):667-76.
  • 2) Okazaki T, Honjo T. PD1 and PD1 ligands: from discovery to clinical application. İnternational Immunol 2007(19);7:813.
  • 3) Droeser RA, Hirt C, Viehl CT. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer Eur J Cancer. 2013;49(9):2233-42.
  • 4) Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD1 and PDL1 inhibitors as a form of cancer immunotherapy: a comprehensive rewiew of registration trials and future considerrations. J Immunother Cancer.2018;6:8.
  • 5) Sibaud V. Eid C. Belum,V. Combemale P. Oral Lichenoid Reactions associated with anti-PD1/PDL1 therapies: clinicopathological findings. J Eur Acad Dermatol Venereol. 2017; 31(10):464-9.
  • 6) Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443.
  • 7) Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711.
  • 8) Pinter A, Patzold S, Kaufmann R. Lichen planus of nails - successful treatment with Alitretinoin. J Dtsch Dermatol Ges 2011;9(12):1033-4.
  • 9) Staubach P. Lichen planus. CME Dermatol 2009;4(2):68-79.
  • 10) Stratigos A, Garbe C, Lebbe C, Malvehy J, Marmo DVl , Pehamberger H, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015;51:1989–2007.
  • 11) Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease. Am J Clin Dermatol 2016;17:491–508.
  • 12) Gambichler T. Gnielka M, Rüddel I, Stockfleth E, Stücker M, Schmitz L Expression of PD‑L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma. Cancer Immunol Immunother.2017.
  • 13) Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and Schabergetal. meta-analysis. J Am Acad Dermatol 2013; 69:121.
  • 14) Zandberg D. E., Strome S. The role of the PDL1:PD1 pathway in squamous cell carcinoma of the head and neck. Oral Oncology Volume 50, Issue 7, July 2014;627-632.
  • 15) Malaspina TAS, Gasparoto TH, Nogueira Costa MR, de Melo EF, Ikoma VMV, Damante JH, et al, Enhanced programmed death 1 (PD1) and PD1 ligand (PDL1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Immunother 2011;60:965–974.
  • 16) Tsao MS, Kerr KM, Dacic S, Yatabe Y, Hırsch FR, International association for the study of lung cancer, Aurora, CO, USA,Atlas of PDL1 ımmunohistochemistry testing in lung cancer.2017;1-127.
  • 17) Paravina M, Hypertrophic Lichen Planus. A Case Report Serbian Journal of Dermatology and Venereology 2014;6(2):73-80.
  • 18) Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE et al. Cytotoxic cutaneous adverse drug reactions during anti-PD1 therapy. Clin Cancer Res 2016; 22(16):4023–9.
  • 19) Nishimura H, Okazaki T, Tanaka Y, K Nakatani, M Hara, A Matsumori et al. Autoimmune dilated cardiomyopathy in PD1 receptor-deficient mice . Science 2001; 291(5502):319–22.
  • 20) Chang CH, Chang SY, Lee HL Lin HM, Bullous lichen planus-like reactions in a patient with renal cancer after receiving anti-programmed cell death -1 therapy. Dermatologica Sinica.2020;55-58.
  • 21) Ziemer M. Lichenoid drug eruption (drug-induced lichen planus).Mockenhaupt M., section ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com (last accessed on Nov 21, 2017).
  • 22) Malaspina SS, Gasparoto HT, Costa MRSN, Melo EF, Enhanced programmed death 1 (PD1) and PD1 ligand (PDL1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Immunother 2011;60:965–974.
  • 23) Hwang SJE, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. JAAD. 2016;74:455–461.
  • 24) Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, et al. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019 Nov;121(10):809–18.
  • 25) Valentini AM, Di Pinto F, Cariola F, Guerra V, Giannelli G, Caruso ML, et al. PDL1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. Oncotarget. 2018;2;9(9):8584–96.
  • 26) Dai, S., Jia, R., Zhang, X., Fang, Q., & Huang, L.. The PD1/PD-Ls pathway and autoimmune diseases. Cellular Immunology, 2014;290(1), 72– 79.
  • 27) Zhou, G., Zhang, J., Ren, X. W., Hu, J. Y., Du, G. F., & Xu, X. Y. Increased B7–H1 expression on peripheral blood T cells in oral lichen planus correlated with disease severity. Journal of Clinical Immunology, 2012;32(4), 794–801.
  • 28) Forouzan P, Riahi RR, Cohen PR. Atorvastatin-induced Lichenoid Drug Eruption: A Case Report and Review of Statin-associated Cutaneous Adverse Events. Cureus. 2020;1;12(3):e7155.
  • 29) Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker MJ, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol. 2009;61(1):104–11.

Derinin Skuamöz Hücreli Karsinomunda ve Liken Planusta PDL1, PD1 Ekspresyonlarının Değerlendirilmesi

Year 2021, Volume: 12 Issue: 2, 147 - 157, 20.08.2021

Gamze Erkılınç , Onur Ertunç , Mehmet Kıran , Nermin Karahan , Havva Hilal Ayvaz , Dudu Dilek Yavuz , Zümrüt Arda Kaymak

https://doi.org/10.22312/sdusbed.816756

Abstract

Amaç: Programlı hücre ölümü 1 (PD1) T hücre ailesinde olan immün sistemi “down” regüle eden bir proteindir. PD ligandı 1 (PDL1) T hücre proliferasyonunu ve sitokin üretimini inhibe eden PD1 reseptör proteinidir. Dermiste lenfositik reaksiyon Liken Planusta (LP) lezyonun özelliği iken Skuamöz Hücreli Karsinomada (SHK) tümör hücrelerine karşı gelişen bir cevap olarak da izlenebilir. Çalışmamızda SHK ve LP’de PD1, PDL1’in epidermis ve lenfositik hücrelerdeki ekspresyonunu karşılaştırmayı amaçladık.
Materyal ve Method: Retrospektif randomize olarak dermiste LHİ (lenfositik hücre infiltrasyonu) yaygın olan 31 SCC ve 38 LP tanılı olgu çalışmamıza dahil edildi. PD1, PDL1’in; SHK, LP’ lerde dermisteki LHİ ekspresyonu ve epidermisteki hücrelerdeki ekspresyonları skorlandı.
Bulgular: PD1’in LHİ skoru LP’lerde anlamlı şekilde skor 1 ve 2 sık görülür iken (sırasıyla %44.7, %34.2), SHK’larda çoğunlukla skor 0 (%67.7) idi. PD1’in LP, SHK’da skor 3 hiç görülmez iken her iki grupta skor 0 çoğunlukta saptandı (LP: %76.3, SHK %87.1). PDL1’in LHİ skoru LP, SHK’da çoğunlukla skor 2, 3 olarak saptandı. PDL1’in deri skoru LP’lerde skor 2 ve 3 hiç görülmezken SHK’larda skor 2 %9.7, skor 3 %6.5 oranında görüldü.
Sonuç: PD1, PDL1 ile LP’lerin SHK’lara göre anlamlı şekilde lenfositik hücrelerde ekspresyonu, neoplastik durumlarda kullanımı sonrası yan etki olarak görülen LP ve benzeri deri reaksiyonlarını açıklayabileceğini düşünmekteyiz.

Keywords

PDL1 PD1 Skuamöz Hücreli Karsinoma Liken Planus

References

  • 1) Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD1) positive tumor infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013;139(3):667-76.
  • 2) Okazaki T, Honjo T. PD1 and PD1 ligands: from discovery to clinical application. İnternational Immunol 2007(19);7:813.
  • 3) Droeser RA, Hirt C, Viehl CT. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer Eur J Cancer. 2013;49(9):2233-42.
  • 4) Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD1 and PDL1 inhibitors as a form of cancer immunotherapy: a comprehensive rewiew of registration trials and future considerrations. J Immunother Cancer.2018;6:8.
  • 5) Sibaud V. Eid C. Belum,V. Combemale P. Oral Lichenoid Reactions associated with anti-PD1/PDL1 therapies: clinicopathological findings. J Eur Acad Dermatol Venereol. 2017; 31(10):464-9.
  • 6) Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443.
  • 7) Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711.
  • 8) Pinter A, Patzold S, Kaufmann R. Lichen planus of nails - successful treatment with Alitretinoin. J Dtsch Dermatol Ges 2011;9(12):1033-4.
  • 9) Staubach P. Lichen planus. CME Dermatol 2009;4(2):68-79.
  • 10) Stratigos A, Garbe C, Lebbe C, Malvehy J, Marmo DVl , Pehamberger H, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015;51:1989–2007.
  • 11) Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease. Am J Clin Dermatol 2016;17:491–508.
  • 12) Gambichler T. Gnielka M, Rüddel I, Stockfleth E, Stücker M, Schmitz L Expression of PD‑L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma. Cancer Immunol Immunother.2017.
  • 13) Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and Schabergetal. meta-analysis. J Am Acad Dermatol 2013; 69:121.
  • 14) Zandberg D. E., Strome S. The role of the PDL1:PD1 pathway in squamous cell carcinoma of the head and neck. Oral Oncology Volume 50, Issue 7, July 2014;627-632.
  • 15) Malaspina TAS, Gasparoto TH, Nogueira Costa MR, de Melo EF, Ikoma VMV, Damante JH, et al, Enhanced programmed death 1 (PD1) and PD1 ligand (PDL1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Immunother 2011;60:965–974.
  • 16) Tsao MS, Kerr KM, Dacic S, Yatabe Y, Hırsch FR, International association for the study of lung cancer, Aurora, CO, USA,Atlas of PDL1 ımmunohistochemistry testing in lung cancer.2017;1-127.
  • 17) Paravina M, Hypertrophic Lichen Planus. A Case Report Serbian Journal of Dermatology and Venereology 2014;6(2):73-80.
  • 18) Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE et al. Cytotoxic cutaneous adverse drug reactions during anti-PD1 therapy. Clin Cancer Res 2016; 22(16):4023–9.
  • 19) Nishimura H, Okazaki T, Tanaka Y, K Nakatani, M Hara, A Matsumori et al. Autoimmune dilated cardiomyopathy in PD1 receptor-deficient mice . Science 2001; 291(5502):319–22.
  • 20) Chang CH, Chang SY, Lee HL Lin HM, Bullous lichen planus-like reactions in a patient with renal cancer after receiving anti-programmed cell death -1 therapy. Dermatologica Sinica.2020;55-58.
  • 21) Ziemer M. Lichenoid drug eruption (drug-induced lichen planus).Mockenhaupt M., section ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com (last accessed on Nov 21, 2017).
  • 22) Malaspina SS, Gasparoto HT, Costa MRSN, Melo EF, Enhanced programmed death 1 (PD1) and PD1 ligand (PDL1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Immunother 2011;60:965–974.
  • 23) Hwang SJE, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. JAAD. 2016;74:455–461.
  • 24) Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, et al. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019 Nov;121(10):809–18.
  • 25) Valentini AM, Di Pinto F, Cariola F, Guerra V, Giannelli G, Caruso ML, et al. PDL1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. Oncotarget. 2018;2;9(9):8584–96.
  • 26) Dai, S., Jia, R., Zhang, X., Fang, Q., & Huang, L.. The PD1/PD-Ls pathway and autoimmune diseases. Cellular Immunology, 2014;290(1), 72– 79.
  • 27) Zhou, G., Zhang, J., Ren, X. W., Hu, J. Y., Du, G. F., & Xu, X. Y. Increased B7–H1 expression on peripheral blood T cells in oral lichen planus correlated with disease severity. Journal of Clinical Immunology, 2012;32(4), 794–801.
  • 28) Forouzan P, Riahi RR, Cohen PR. Atorvastatin-induced Lichenoid Drug Eruption: A Case Report and Review of Statin-associated Cutaneous Adverse Events. Cureus. 2020;1;12(3):e7155.
  • 29) Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker MJ, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol. 2009;61(1):104–11.
There are 29 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Original Article
Authors

Gamze Erkılınç 0000-0003-4704-7415

Onur Ertunç 0000-0002-4159-1711

Mehmet Kıran 0000-0003-3292-2213

Nermin Karahan 0000-0003-0883-4037

Havva Hilal Ayvaz 0000-0002-6576-2431

Dudu Dilek Yavuz 0000-0001-9654-9097

Zümrüt Arda Kaymak 0000-0002-7284-008X

Publication Date August 20, 2021
Submission Date October 27, 2020
Published in Issue Year 2021 Volume: 12 Issue: 2

Cite

Vancouver Erkılınç G, Ertunç O, Kıran M, Karahan N, Ayvaz HH, Yavuz DD, Kaymak ZA. Evaluation of PD1 and PDL1 Expressions in Squamous Cell Carcinoma and Lichen Planus. Süleyman Demirel Üniversitesi Sağlık Bilimleri Dergisi. 2021;12(2):147-5.
 Download Cover Image

SDÜ Sağlık Bilimleri Dergisi, makalenin gönderilmesi ve yayınlanması dahil olmak üzere hiçbir aşamada herhangi bir ücret talep etmemektedir. Dergimiz, bilimsel araştırmaları okuyucuya ücretsiz sunmanın bilginin küresel paylaşımını artıracağı ilkesini benimseyerek, içeriğine anında açık erişim sağlamaktadır.